Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00265642
Status:
COMPLETED
Last Update Posted:
2014-02-07
First Post:
2005-12-14
Brief Title:
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
Sponsor:
ANRS Emerging Infectious Diseases
Organization:
ANRS Emerging Infectious Diseases
Study Overview
Official Title:
Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Fibrosar
Brief Summary:
The purpose of this study is to examine the efficacy of irbesartan on the progression of liver fibrosis in adult patients with chronic hepatitis C
The expected total enrollment is 200 patients Patients who meet the study criteria and accept to participate at this study will take by day one tablet of 150 mg of treatment irbesartan or placebo during two years The assessment of efficacy will be make by evaluation of area of liver fibrosis and blood markers of liver fibrosis
The expected total enrollment is 200 patients Patients who meet the study criteria and accept to participate at this study will take by day one tablet of 150 mg of treatment irbesartan or placebo during two years The assessment of efficacy will be make by evaluation of area of liver fibrosis and blood markers of liver fibrosis
Detailed Description:
The results of several studies suggests than the AT1 receptor antagonists of angiotensin II have inhibitory effects on TGF-beta 1 production and can limit the progression of liver fibrosis
Therefore the angiotensin II could be another mediator of the synthesis of the extra-cellular matrix at the hepatic level opening new perspectives with the antagonists of angiotensin II receptors drugs ARA2sartans
This study is a randomized double blind multi-center parallel assignment and efficacy study
Therefore the angiotensin II could be another mediator of the synthesis of the extra-cellular matrix at the hepatic level opening new perspectives with the antagonists of angiotensin II receptors drugs ARA2sartans
This study is a randomized double blind multi-center parallel assignment and efficacy study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ANRS HC 19 Fibrosar | None | None | None |